1. Home
  2. MIRA vs IXHL Comparison

MIRA vs IXHL Comparison

Compare MIRA & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MIRA Pharmaceuticals Inc.

MIRA

MIRA Pharmaceuticals Inc.

HOLD

Current Price

$0.75

Market Cap

37.1M

Sector

Health Care

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$3.65

Market Cap

37.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRA
IXHL
Founded
2020
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.1M
37.0M
IPO Year
2023
2024

Fundamental Metrics

Financial Performance
Metric
MIRA
IXHL
Price
$0.75
$3.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
87.1K
81.1K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$0.16
52 Week High
$2.45
$6.39

Technical Indicators

Market Signals
Indicator
MIRA
IXHL
Relative Strength Index (RSI) 44.45 67.06
Support Level $0.72 $2.79
Resistance Level $0.83 $4.03
Average True Range (ATR) 0.05 0.16
MACD 0.01 0.06
Stochastic Oscillator 28.67 71.76

Price Performance

Historical Comparison
MIRA
IXHL

About MIRA MIRA Pharmaceuticals Inc.

Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: